Abstract

Glaukos will report its fourth-quarter 2025 results on February 17, 2026 Post Market; this preview outlines consensus revenue growth near the mid-30% range, margin dynamics amid product mix shifts, and analyst expectations anchored by the iDose TR ramp and glaucoma franchise performance.

Market Forecast

The market anticipates a solid quarter for Glaukos with current-quarter revenue estimated at $136.40 million, reflecting a 35.42% year-over-year increase, alongside forecast EBIT of -$12.92 million and forecast EPS of -$0.20; consensus expects ongoing gross margin support from a richer mix and operating leverage, while net margin remains negative but improving year over year. The company’s previous report and guidance imply sustained momentum in its glaucoma and corneal health portfolio, with continued rollout of iDose TR supporting top-line growth and an improving adjusted EPS trajectory from the prior quarter’s beat.

Glaukos’s glaucoma franchise remains the revenue anchor, while corneal health contributes a smaller but growing portion; management and market commentary focus on iDose TR uptake, channel expansion, and steady procedure volumes. The most promising segment is glaucoma, with last quarter revenue of $110.25 million and a year-over-year growth rate above company average referenced in analyst commentary, supported by accelerating iDose TR adoption.

Last Quarter Review

In the last reported quarter, Glaukos delivered revenue of $133.54 million with a gross profit margin of 78.41%, a GAAP net loss attributable to the parent of $16.23 million translating to a net profit margin of -12.15%, and adjusted EPS of -$0.16; revenue grew 38.14% year over year, and adjusted EPS improved year over year. A key highlight was the company’s top-line outperformance versus prior estimates, accompanied by an EBIT loss narrower than forecast, reflecting operating efficiency gains during the iDose TR ramp. Main business highlights included glaucoma revenue of $110.25 million and corneal health revenue of $23.29 million, with glaucoma demonstrating the stronger growth trajectory driven by expanding utilization.

Current Quarter Outlook (with major analytical insights)

Main business: Glaucoma portfolio momentum with iDose TR ramp

Glaukos’s glaucoma franchise is positioned to extend its growth trend into the fourth quarter of 2025, underpinned by increasing iDose TR penetration and stable micro-invasive glaucoma surgery (MIGS) demand. Unit uptake for iDose TR is expected to expand as new accounts come online and existing prescriber productivity improves, supporting revenue leverage within the franchise. Pricing remains constructive for the glaucoma mix, helping to sustain gross margins that approached the high-70% range last quarter, though scale effects and launch investments still weigh on operating margins. The key watch items this quarter are new account additions, refill dynamics, and any updates to procedure utilization, which collectively inform the durability of growth into 2026.

Most promising business: iDose TR adoption and trajectory

Analysts broadly characterize iDose TR as the leading growth engine for Glaukos, citing accelerating adoption curves and a long runway in both prevalent and incident patient cohorts. As distribution broadens and clinical comfort increases among ophthalmologists, the product’s contribution to overall glaucoma revenue should rise further in Q4, with upside potential from improved procedure throughput and refill cadence. The near-term profit profile remains shaped by commercialization investments; however, as volumes ramp, manufacturing absorption and fixed-cost leverage could gradually reduce EBIT losses, reflected in the consensus expectation for a smaller EPS loss this quarter versus earlier periods. Any commentary on payer dynamics, billing efficiency, or real-world adherence could influence post-report revisions to 2026 revenue models.

Stock-price drivers this quarter: Margins, operating spend, and guidance cadence

The principal stock-price sensitivities are likely to be gross margin trajectory, the cadence of selling and marketing expense as iDose TR scales, and the quality of management’s commentary on 2026 growth and profitability milestones. A gross margin print consistent with or improving from last quarter’s 78.41% would reinforce confidence that mix and scale are offsetting launch costs; conversely, any softness from product or channel mix would prompt debate about the near-term earnings path. Investors will also scrutinize operating expense intensity relative to the forecast revenue base of $136.40 million, looking for evidence of discipline as commercial infrastructure matures. Guidance color around patient funnel expansion, refill rates, and international timelines may shape how far the recent growth can extend and whether operating leverage can begin to show more tangibly into the first half of 2026.

Analyst Opinions

Analyst sentiment over the past six months is predominantly bullish, with several well-known institutions reiterating positive views and higher targets. Needham maintained a Buy rating with a $125.00 price target, highlighting multi-segment growth and a constructive iDose TR trajectory as core drivers. Wells Fargo reiterated a Buy rating with a $122.00 target, reflecting confidence in the company’s execution and revenue ramp. BTIG also kept a Buy rating with a $118.00 target, citing strong growth and product potential across the glaucoma portfolio. Truist Financial reaffirmed its Buy stance, emphasizing continued momentum in core businesses and the potential for upside as iDose TR adoption advances. Stifel Nicolaus repeatedly reaffirmed Buy ratings with a $115.00 target during the period, underscoring durable fundamentals and traction in the launch. Based on the collected views, bullish opinions comprise the overwhelming majority compared with bearish takes, and the majority perspective expects Glaukos to deliver above-trend revenue growth in Q4 with supportive gross margins and a narrowing EPS loss. The crux of the bullish case is that iDose TR is still in early phases of market penetration, creating a multi-quarter avenue for sustained top-line expansion and gradual operating leverage, while the legacy glaucoma base and corneal health provide stability to the revenue mix.